Please login to the form below

Not currently logged in
Email:
Password:

Kremers Urban

This page shows the latest Kremers Urban news and features for those working in and with pharma, biotech and healthcare.

UCB boosted by core medicines growth

UCB boosted by core medicines growth

The firm had been poised to sell its Kremers Urban generics business in order to focus almost exclusively on patented medicines, but the $1.5bn sale fell through in December after ... The Belgian pharma firm remains optimistic about its overall finances,

Latest news

  • UCB's $1.53bn generics sale falls through UCB's $1.53bn generics sale falls through

    The private equity buyers of UCB's US generics unit Kremers Urban Pharmaceuticals have backed away from the proposed $1.53bn deal. ... Kremers Urban has already said it intends to perform the requested additional study.

  • UCB to sell its US generics business for $1.5bn UCB to sell its US generics business for $1.5bn

    Belgium-based pharma company UCB has agreed to sell its generics subsidiary Kremers Urban Pharmaceuticals for $1.5bn. ... We thank our Kremers Urban colleagues for the excellent performance they have delivered.

  • Novartis said to want out of Indian vaccines venture Novartis said to want out of Indian vaccines venture

    It also forged two new collaborations for generic pharmaceutical products signed towards the end of last year with UCB subsidiary Kremers Urban Pharmaceuticals and Osmotica Pharmaceutical.

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Redline Strategic

We are a healthcare consultancy, specialising in people and experiences. Using innovative research methods to capture the thoughts of real...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics